ModifiedCignaPolicy IP0075

Wakefulness-Promoting Agents – Armodafinil, Modafinil - (IP0075)

Defines Cigna prior authorization, step therapy, and medical necessity criteria for armodafinil and modafinil (brand and generic) across approved indications and selected supportive-evidence uses; lists noncovered indications and documentation requirements. Applies to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyWakefulness-Promoting Agents – Armodafinil, Modafinil - (IP0075)

Policy CodePolicy IP0075

Change TypeRevised criteria and documentation requirements; specialist prescribing clarified; brand exception specified

Effective Date

Next Review Date

Key ActionPrior authorization is required for all brand and generic modafinil and armodafinil claims; provide required documentation and follow step therapy and specialist prescribing requirements as specified.

SourceLink

POLICY UPDATE CHANGES

Added requirement that for certain indications medication be prescribed by or in consultation with a physician who specializes in the condition being treated.

Updated narcolepsy criteria wording to require documentation that patient has been evaluated using polysomnography and multiple sleep latency test and confirm diagnosis.

Obstructive sleep apnea criteria changed to allow use in conjunction with positive airway pressure (CPAP, APAP, or BPAP) or when patient is unable to initiate or tolerate positive airway pressure.

Idiopathic hypersomnia criteria updated to require polysomnography and MSLT evaluation with congruent results and specialist prescribing/consultation.

Updated documentation verbiage throughout criteria to use standardized '[documentation required]' phrasing.

Removed pulmonologist from lists of prescribing/consult specialists in multiple indications.

Employer/Individual plan exception criteria for brand products when bioequivalent generic trial failed due to inactive ingredient allergy/intolerance were specified.

3FDA-Approved Indications Covered

5Supportive Evidence Indications Covered

10Listed Not-Covered Conditions

Coverage Summary & Scope

Defines Cigna prior authorization, step therapy, and medical necessity criteria for armodafinil and modafinil (brand and generic) across FDA-approved indications (narcolepsy, obstructive sleep apnea adjunctive therapy, shift work sleep disorder) and selected supportive-evidence uses; lists noncovered indications and documentation requirements. Applies to health benefit plans administered by Cigna Companies.

These agents are Schedule IV controlled substances. The policy references relevant guidelines from the American Academy of Sleep Medicine (AASM) for hypersomnolence and OSA and requires documentation and, for certain indications, specialist prescribing or consultation.

Policy-level key facts

Age≥ 18 years

Shift work frequencyWorks at least five overnight shifts per month

Policy identifierIP0075

StatusMODIFIED

Last review2026-04-01

Prior Authorization, Step Therapy, and Documentation (General)

General Prior Authorization and Step Therapy

Prior Authorization is required for benefit coverage of modafinil and armodafinil. When clinically appropriate, patient must try a Step 1 product (generic modafinil or generic armodafinil) prior to brand. Approvals are provided for the durations noted in indication-specific criteria.

General requirements

PA requirement: Prior Authorization required for modafinil (brand and generic) and armodafinil (brand and generic)
Specialist prescribing/consultation: For certain indications, medication must be prescribed by or in consultation with a physician who specializes in the condition being treated (sleep specialist physician or a neurologist for specified indications)
Documentation is required where noted in the criteria and may include chart notes, laboratory tests, claims records, and/or other information (must include patient-specific identifying information)

FDA‑Approved Indications — Authorization Criteria

FDA-Approved Indications - Medically Necessary Criteria

Modafinil and armodafinil are considered medically necessary when ONE of the following FDA-approved indication-specific sets of criteria is met. Approvals noted are for 1 year where specified.

One of the following indications

1. Excessive Daytime Sleepiness Associated with Narcolepsy: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Patient has been evaluated using polysomnography and a multiple sleep latency test [documentation required]; Diagnosis of narcolepsy has been confirmed [documentation required]; Medication is prescribed by or in consultation with a sleep specialist physician or a neurologist; Preferred product criteria is met
[documentation required]
2. Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Patient meets one of: (i) armodafinil/modafinil will be used in conjunction with positive airway pressure therapy (CPAP, APAP, or BPAP); OR (ii) patient is unable to initiate or tolerate positive airway pressure therapy [documentation required]; Preferred product criteria is met

Other Uses with Supportive Evidence — Authorization Criteria

Other Uses with Supportive Evidence - Medically Necessary Criteria

Approvals for supportive-evidence uses are for 1 year if all listed criteria are met.

One of the following supportive-evidence indications

4. Adjunctive/Augmentation Treatment for Depression in Adults: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Patient is concurrently receiving other medication therapy for depression [documentation required]; Preferred product criteria is met
[documentation required]
5. Excessive Daytime Sleepiness Associated with Myotonic Dystrophy: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Preferred product criteria is met
6. Excessive Daytime Sleepiness Associated with Parkinson's Disease:

Brand Product Exceptions (Employer / Individual Plans)

Brand-specific Employer/Individual Plan Criteria

Exceptions allowing brand product coverage when bioequivalent generic trial fails due to inactive ingredient intolerance.

Brand-specific exceptions by plan type

Nuvigil (armodafinil) - Employer Plans: Patient has tried the bioequivalent generic product, armodafinil; AND patient cannot take the generic due to a formulation difference in the inactive ingredient(s) that would result, per the prescriber, in a significant allergy or serious adverse reaction
Provigil (modafinil) - Employer Plans: Patient has tried the bioequivalent generic product, modafinil; AND patient cannot take the generic due to a formulation difference in the inactive ingredient(s) that would result, per the prescriber, in a significant allergy or serious adverse reaction
Nuvigil (armodafinil) - Individual and Family Plan:

Not Medically Necessary / Exclusions

Not Medically Necessary / Not Covered Conditions

Modafinil and armodafinil are considered not medically necessary for any other use not listed in the Recommended Authorization Criteria, including but not limited to the following.

Excluded / Not Covered Conditions

Attention Deficit Hyperactivity Disorder (ADHD)
Bipolar Disorder, including Bipolar Depression
Cancer-Related Fatigue
Chronic Fatigue Syndrome
Excessive Daytime Sleepiness Associated with Primary Insomnia

Codes & Policy Identifiers

Policy identifiersmixed

IP0075

Coverage Policy Number

Clinical Evidence & Guideline Context

AASM recommendations (2021): Modafinil is recommended as an effective treatment for daytime sleepiness due to narcolepsy (Strong Recommendation); armodafinil has Conditional Recommendation evidence for narcolepsy. AASM guidance (2021) also provides conditional and strong recommendations across central disorders of hypersomnolence including idiopathic hypersomnia and other secondary hypersomnias.

AASM OSA guideline (2019): Positive airway pressure (PAP) therapy (CPAP/APAP/BPAP) is recommended as primary treatment for OSA with excessive sleepiness; modafinil/armodafinil may be used as adjunctive therapy when PAP is used or when PAP is not tolerated.

Many off-label uses of modafinil/armodafinil are considered investigational or not supported by sufficient evidence; the policy lists multiple not-medically-necessary conditions (e.g., ADHD, bipolar disorder, cancer-related fatigue, chronic fatigue syndrome, enhancement of performance, fibromyalgia, post-stroke sleep-wake disorders).

Guideline / Evidence highlights

AASM (2021) - NarcolepsyModafinil recommended as effective for daytime sleepiness due to narcolepsy (Strong); armodafinil conditional

AASM OSA Guideline (2019)PAP therapy recommended; modafinil/armodafinil may be adjunctive when PAP is used or not tolerated

Definitions

Documentation: May include chart notes, laboratory tests, claims records, and/or other information and must include patient-specific identifying information. Documentation is required where noted in the criteria as [documentation required].

Positive airway pressure (PAP): Includes continuous positive airway pressure (CPAP), auto-titrating positive airway pressure (APAP), or bilevel positive airway pressure (BPAP).

Revision History

2026-04-01revisedLatest

Added requirement that for certain indications medication be prescribed by or in consultation with a physician who specializes in the condition being treated. (Change reflected 4/1/2026 revision note; emphasizes specialist involvement due to specialized skills and monitoring.)

2026-04-01revisedLatest

Updated narcolepsy criteria wording to require documentation that patient has been evaluated using polysomnography and multiple sleep latency test and confirm diagnosis. (Replaced more prescriptive MSLT/SOREMP technical language with documentation requirement; multiple prior editorial removals consolidated.)

Policy Summary

PayerCigna

PolicyWakefulness-Promoting Agents – Armodafinil, Modafinil - (IP0075)

Policy CodePolicy IP0075

Change TypeRevised criteria and documentation requirements; specialist prescribing clarified; brand exception specified

Effective Date

Next Review Date

SourceLink

On This Page

Step therapy: Step Therapy: patient directed to try one Step 1 Product (generic modafinil or generic armodafinil) prior to brand Nuvigil or brand Provigil when clinically appropriate

title": "General Prior Authorization and Step Therapy"

Prior Authorization

Prior Authorization Required

Prior authorization is required for all brand and generic modafinil and armodafinil claims; approvals are indication-specific and provided for the durations noted (typically 1 year).

Documentation Required

Provide documentation where noted (e.g., polysomnography and multiple sleep latency test results, confirmation of diagnosis, evidence of inability to tolerate positive airway pressure, work schedule, concurrent depression therapy); documentation must include patient identifiers.

Step Therapy

Step Therapy / Preferred Product Trial

When clinically appropriate, patient should try a Step 1 product (generic modafinil or generic armodafinil) prior to coverage of brand Nuvigil or Provigil; employer/individual plan exceptions permit brand only if generic trial failed due to inactive-ingredient allergy/intolerance per prescriber.

Documentation Required

Specialist Prescribing / Consultation Requirement

For certain indications, medication must be prescribed by or in consultation with a physician who specializes in the condition being treated (sleep specialist or neurologist specified for several indications).

Denial Risk

Denial Risk for Non‑Listed Uses

Claims for uses not meeting the listed authorization criteria (including listed excluded conditions) will be denied as not medically necessary.

[documentation required]

3. Excessive Sleepiness Associated with Shift Work Sleep Disorder: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Patient works at least five overnight shifts per month [documentation required]; Preferred product criteria is met

[documentation required]

Approvals are typically provided for 1 year when criteria are met. Preferred product criteria tables and coding/preferred product details are referenced elsewhere in the policy (see the preferred product criteria / coding sections).

Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Preferred product criteria is met

7. Fatigue Associated with Multiple Sclerosis: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Preferred product criteria is met

8. Idiopathic Hypersomnia: Approve for 1 year if all of the following are met: Patient is ≥ 18 years of age; Patient has been evaluated using polysomnography and a multiple sleep latency test [documentation required]; Results of the polysomnography and multiple sleep latency test are congruent with a diagnosis of idiopathic hypersomnia [documentation required]; Medication has been prescribed by or in consultation with a sleep specialist or a neurologist; Preferred product criteria is met

[documentation required]

Approvals for the included FDA-approved and supportive-evidence uses are for 1 year when the indication-specific criteria are satisfied.

Patient has tried the bioequivalent generic product, armodafinil; AND patient cannot take the generic due to a formulation difference in the inactive ingredient(s) that would result, per the prescriber, in a significant allergy or serious adverse reaction

Provigil (modafinil) - Individual and Family Plan: Patient has tried the bioequivalent generic product, modafinil; AND patient cannot take the generic due to a formulation difference in the inactive ingredient(s) that would result, per the prescriber, in a significant allergy or serious adverse reaction

Billing Rule

Brand Exception: Inactive Ingredient Intolerance

Brand coverage is allowed only when the patient has tried the bioequivalent generic (armodafinil for Nuvigil or modafinil for Provigil) and, per the prescriber, cannot take the generic due to a formulation difference in inactive ingredient(s) that would result in a significant allergy or serious adverse reaction.

Enhancement of Performance in Situations of Induced Sleep Deprivation (general population)

Hypersomnia, Fatigue or Sleepiness Due to Other Conditions (not Idiopathic Hypersomnia)

Post-Stroke Sleep-Wake Disorders or Sleep Disorders

Any circumstance not listed in the Recommended Authorization Criteria

Denial Risk

Denied When Not Meeting Criteria

Uses that do not meet the authorization criteria will be denied as not medically necessary.

APA (2010) - Depression

Modafinil may be used as adjunctive treatment for sedation/residual symptoms with antidepressants

Idiopathic Hypersomnia (AASM 2021)Only modafinil has a Strong Recommendation; others conditional

Policy guideline summaryPrior authorization required; Step therapy prefers generic before brand

2026-03-01revised

Obstructive sleep apnea criteria changed to allow use in conjunction with positive airway pressure (CPAP, APAP, or BPAP) or when patient is unable to initiate or tolerate positive airway pressure; removed prior requirement for documented inadequate response to at least 1 month of non-pharmacologic treatment and updated documentation verbiage to '[documentation required]'.

2026-04-01revisedLatest

Idiopathic hypersomnia criteria updated to require polysomnography and MSLT evaluation with congruent results and specialist prescribing/consultation; diagnostic documentation requirement clarified. (Previously removed and re-added diagnostic documentation in different revisions; current policy requires documented evaluation and congruent results.)

2026-04-01clarifiedLatest

Administrative change to documentation wording across multiple indications: documentation verbiage standardized to '[documentation required]'.

2024-10-15revised

Specialist requirements narrowed: pulmonologist removed from lists of prescribing/consult specialists in multiple indications (sleep specialist and neurologist specified).

2026-04-01addedLatest

Employer/Individual plan exception criteria specified for brand product coverage when bioequivalent generic trial failed due to a formulation difference in inactive ingredient(s) causing, per prescriber, a significant allergy or serious adverse reaction.